Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Daniela, Lang, Michael, Harth, Andreas, Naumann, Markus, Weber, Frank, Tumani, Hayrettin, Bayas, Antonios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/
https://www.ncbi.nlm.nih.gov/pubmed/26132570
http://dx.doi.org/10.3390/ijms160714669
_version_ 1782383566633566208
author Rau, Daniela
Lang, Michael
Harth, Andreas
Naumann, Markus
Weber, Frank
Tumani, Hayrettin
Bayas, Antonios
author_facet Rau, Daniela
Lang, Michael
Harth, Andreas
Naumann, Markus
Weber, Frank
Tumani, Hayrettin
Bayas, Antonios
author_sort Rau, Daniela
collection PubMed
description Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.
format Online
Article
Text
id pubmed-4519865
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-45198652015-08-03 Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases Rau, Daniela Lang, Michael Harth, Andreas Naumann, Markus Weber, Frank Tumani, Hayrettin Bayas, Antonios Int J Mol Sci Case Report Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication. MDPI 2015-06-29 /pmc/articles/PMC4519865/ /pubmed/26132570 http://dx.doi.org/10.3390/ijms160714669 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Rau, Daniela
Lang, Michael
Harth, Andreas
Naumann, Markus
Weber, Frank
Tumani, Hayrettin
Bayas, Antonios
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title_full Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title_fullStr Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title_full_unstemmed Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title_short Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
title_sort listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/
https://www.ncbi.nlm.nih.gov/pubmed/26132570
http://dx.doi.org/10.3390/ijms160714669
work_keys_str_mv AT raudaniela listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT langmichael listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT harthandreas listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT naumannmarkus listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT weberfrank listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT tumanihayrettin listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases
AT bayasantonios listeriameningitiscomplicatingalemtuzumabtreatmentinmultiplesclerosisreportoftwocases

Ejemplares similares